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104HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of
the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active
antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among
treated individuals exceeds 50%. The goal of our systematic review is to examine published clinical studies
involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based
recommendations based on published efficacy and safety data. A systematic review of the published
literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on
published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other
reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for
treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administra-
tion indication of subdermal implantation, may be best used deeply over bone for focal enhancement.
Additional long-term randomized controlled trials are necessary to elucidate the advantages and
disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness
analysis, for treatment of HIV FLA. ( J Am Acad Dermatol 2015;73:1040-54.)
Key words: facial volume loss; filler agent; highly active antiretroviral therapy; HIV facial lipoatrophy; HIV
lipodystrophy; quality of life.H
IV facial lipoatrophy (FLA) is a subtype of
HIV lipodystrophy associated with the use
of highly active antiretroviral therapy
(HAART),1 and is characterized by facial volume
loss that affects the contours of the cheeks, temples,
and orbits. HIV FLA is socially stigmatizing and
impacts patients’ adherence to HAART,2,3 psycho-
logical health, and quality of life (QoL), including
feelings of distress, depression, anxiety, social isola-
tion, and career barriers.4
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Jagdeo et al 1041social function, and emotional status.8,9 Most pub-
lished studies on the efficacy and safety of filler agents
for treatment of HIV FLA have been observational
studies. A grading criteria used for classification ofHIV
FLA severity, Carruthers Lipoatrophy Severity Scale, is
also often used as a standardized measure to assess
response of patients with HIV FLA to treatment withCAPSULE SUMMARY
d HIV facial lipoatrophy is characterized by
facial volume loss and is associated with
social stigma.
d Based on published studies, poly-L-lactic
acid is the only filler agent with grade of
recommendation: B. Other reviewed filler
agents received grade of recommendation:
C or D.
d Filler agents are generally safe for
aesthetic improvement of HIV facial
lipoatrophy and improve patient quality
of life.filler agents (Fig 1).10
The goal of our systematic
review is toexaminepublished
clinical studies involving the
use of filler agents for aesthetic
treatment of HIV FLA and to
provide evidence-based rec-
ommendations based on pub-
lished efficacy and safety data.
METHODS
Search strategy and data
extraction
A systematic review of the
published literature was per-
formed on July 1, 2015, on
filler agents for aesthetic
treatment of HIV FLA (please
see Fig 2 and legend for detailed search strategy).
RESULTS
Study selection of filler agents for aesthetic
treatment of HIV FLA
A total of 321 articles regarding the use of filler
agents for treatment of HIV FLAwere identified. After
screening of titles, abstracts, and full text, 76 original
articles were suitable in our review: poly-L-lactic acid
(PLLA) (29), calcium hydroxylapatite (CaHA) (6),
hyaluronic acid (HA) (7), polyacrylamide gel (PAAG)
(9), polyalkylimide gel (PAIG) (11), polymethylme-
thacrylate (PMMA) (6), silicone oil (2), and autolo-
gous fat transfer (AFT) (6).
Articles were assigned a level of evidence (LOE)
and graded according to the Oxford Center for
Evidence-based Medicine LOE grades of recommen-
dation (GOR)11 (Table I). A list of filler agents used in
published clinical studies for aesthetic treatment of
HIV FLA can be found in Table II and detailed
information on published clinical studies using filler
agents for aesthetic treatment ofHIV FLA can be found
on http://www.jaad.org in Supplemental Table I.
Filler agents for aesthetic treatment of HIV FLA
Food and Drug Administration (FDA)-approved
dermal fillers for treatment of HIV FLA are Sculptra
(Galderma, Fort Worth, TX) (PLLA, 2004) and
Radiesse (Merz Aesthetics, Franksville, WI) (CaHA,
2006). Clinicians have used the following filler agentsoff-label to treat HIV FLA: HA, PAAG, PAIG, PMMA,
silicone oil, and AFT.
FDA approved for treatment of HIV FLA.
Poly-L-lactic acid
PLLA reconstituted in sterile water and lidocaineimproves facial volume loss
by serving as a scaffold, pro-
moting fibroblast prolifera-
tion and neocollagenesis.12
PLLA was FDA approved in
2004 as the first filler agent
for treatment of HIV FLA.
An open-label, random-
ized study of either immedi-
ate or delayed PLLA
treatment for HIV FLA was
performed in 30 patients
with HIV13 (LOE 2b).
Results at 12 weeks showed
significant improvement in
visual analog scale score for
the immediate treatment
group, and improvement invisual analog scale score was maintained from
baseline in both treatment groups at 18 months14
(LOE 2b). The most common delayed adverse event
was injection-site nodules (31%).
A different open-label, randomized study of im-
mediate or delayed PLLA treatment of HIV FLA
evaluated 100 patients with HIV15 (LOE 2b). By
24 weeks, patients with immediate treatment had
significant improvement in FLA severity and QoL
compared with patients with delayed treatment. At
48 weeks, there were significant changes of
increased tissue depth measured by computed to-
mography imaging with subsequent 3-dimensional
volumetric assessments at the maxillary, base of
nasal septum, and mandibular regions for immediate
treatment group patients16 (LOE 2b). Subcutaneous
nodules remained in 10% of patients at week 48.
Another open-label, randomized study of imme-
diate or delayed PLLA or PAIG treatment of HIV FLA
was performed in 134 patients with HIV17 (LOE 2b).
At 24 weeks, patients from the immediate treatment
group had significantly lower FLA severity compared
with patients in the delayed treatment group.
Twenty observational studies evaluated efficacy
and safety of PLLA treatment for HIV FLA, and all
studies reported positive outcomes for improving
FLA severity and achieving high patient satisfac-
tion8,18-36 (LOE 4). Four case reports demonstrated
PLLA treatment for HIV FLA improved FLA severity
up to 24 months37-40 (LOE 5).
Abbreviations used:
AFT: autologous fat transfer
CaHA: calcium hydroxylapatite
FDA: Food and Drug Administration
FLA: facial lipoatrophy
GOR: grade of recommendation
HA: hyaluronic acid
HAART: highly active antiretroviral therapy
LOE: level of evidence
PAAG: polyacrylamide gel
PAIG: polyalkylimide gel
PLLA: poly-L-lactic acid
PMMA: polymethylmethacrylate
QoL: quality of life
RCT: randomized controlled trial
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of HIV FLA based on 3 randomized controlled trials
(RCTs) (with 2 follow-up studies) with LOE 2b, 20
observational studies with LOE 4, and 4 case reports
with LOE 5.
Calcium hydroxylapatite
CaHA, delivered in a soluble carrier gel, acts as a
scaffold for new collagen production. The carrier gelFig 1. Carruthers Lipoatrophy Severity Scale. Gra
Grade 2: deeper and longer atrophy, with the facia
3: atrophic area is even deeper and wider, wi
lipoatrophy covers a wide area, extending up tow
directly on the muscles. (Modified and adapted wis degraded within months of injection and the
remaining CaHA microspheres help promote fibro-
blast growth and new collagen deposition.12 CaHA
was the second filler agent FDA approved in 2006 for
treatment of HIV FLA.
Six studies evaluated the efficacy and safety of
CaHA for treatment of HIV FLA41-46 (LOE 4). Two
different studies showed that CaHA improvement of
FLA severity was maintained for 12 months.44,46 One
study investigated the radiographic properties of
CaHA treatment with x-ray and computed tomo-
graphic imaging,43 and computed tomography
consistently visualized no evidence of CaHA
migration.
Grade of recommendation: C for CaHA treatment
of HIV FLA based on 6 observational studies with
LOE 4.
Off-label filler agents for treatment of HIV FLA.
Hyaluronic acid
HA injectables allow immediate facial volumiza-
tion with release of HA chains from the injected gel
carrier.47de 1: mild and localized facial lipoatrophy.
l muscles beginning to show through. Grade
th the muscles clearly showing. Grade 4:
ard the eye sockets, and the facial skin lies
ith permission from James et al.10)
Fig 2. Schematic of the search strategy listing the number
of articles matching inclusion or exclusion criteria
modified and adapted from Moher et al.90 FLA, Facial
lipoatrophy.
Table I. Level of evidence and grades of
recommendation
LOE
1a. Systematic review of RCTs
1b. Individual RCT
2a. Systematic review of cohort studies
2b. Individual cohort study (including low-quality RCT)
3a. Systematic review of case-control studies
3b. Individual case-control study
4. Case series
5. Case reports, expert opinion, bench research
GOR
A. Studies with consistent LOE 1a and/or 1b
B. Studies with consistent LOE 2a, 2b, 3a, or 3b; or
extrapolations from studies with LOE 1a or 1b
C. Studies with LOE 4 or extrapolations from studies
with LOE 2a, 2b, 3a, or 3b
D. Studies with LOE 5 or troubling inconsistent or
inconclusive studies of any level
Data from Oxford Center for Evidence-based Medicine LOE.11
GOR, Grades of recommendation; LOE, level of evidence; RCT,
randomized controlled trial.
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Jagdeo et al 1043Six observational studies evaluated the efficacy
and safety of HA for treatment of HIV FLA47-52 (LOE
4). HA dermal filler for improvement of HIV FLAwas
sustained for 6 months49 and 12 months47,50,51 with 1
treatment and minimal touch-up. One study
described nodule formation that was effectively
removed using hyaluronidase injectables.47
One case report demonstrated improvement of
FLA severity from baseline of between 2 and 3 to
0 as measured by FLA Severity Scale at 18 months53
(LOE 5).
Grade of recommendation: C for HA treatment of
HIV FLA based on 6 observational studies with LOE 4
and 1 case report with LOE 5.
Polyacrylamide gel
PAAG is a synthetic nonreabsorbable filler that
serves as structural support to restore facial volumeloss.54 PAAG stimulates a fibrotic tissue response
around the implant.
A randomized study evaluated the efficacy and
safety of PAAG administered in 8-mL sessions versus
2-mL sessions every eighth week until full correction
in 31 patients with HIV55 (LOE 2b). At 12 months,
patients who received 8 mL of PAAG over average of
2 sessions showed improvement faster than patients
who received 2 mL of PAAG over average of 7.8
sessions.
Eight different observational studies evaluated the
efficacy and safety of PAAG for treatment of HIV
FLA54,56-62 (LOE 4). Results demonstrated significant
improvement in cheek thickness at 2 years60 and
5 years59 of follow-up.
Grade of recommendation: C for PAAG treatment
of HIV FLA based on 1 RCT with LOE 2b and 8
observational studies with LOE 4.Polyalkylimide gel
PAIG is a nonreabsorbable polymer that provides
structural support for facial volume loss. PAIG in-
duces skin tissue to form a fibrous capsule around
the deposit.63
An open-labeled, randomized study investigated
immediate versus delayed PAIG treatment in 31
patients with HIV9 (LOE 2b). At 12 weeks, immediate
PAIG treatment patients had significantly lower
FLA severity and improved QoL compared with
delayed treatment patients. The median change
in FLA severity at 96 weeks and 4 years was 264
(LOE 2b) and 165 (LOE 2b), respectively. Delayed
Table II. Filler agents for treatment of HIV facial lipoatrophy
Filler Mechanism of action Biophysical properties Formulation Trade names
Product
cost, US$##
PLLA
GOR: B
Three RCTs (with 2 follow-
up studies) with LOE
2b, 20 observational
studies with LOE 4, and
4 case reportswith LOE5.
Stimulates local fibroblasts
to promote
neocollagenesis and
produce new fibrous
dermal tissue to maintain
volume correction after
PLLA microspheres are
naturally degraded by the
body.12
PLLA (of synthetic and
nonanimal origin) is
derived from the alpha-
hydroxy-acid family, and
is commonly used in
resorbable sutures. PLLA
microspheres, packaged
in a freeze-dried
powdered form, is
reconstituted with sterile
water before injection.
Result is not
instantaneous as injection
triggers neocollagenesis
of fibroblast scaffolds
resulting in volumization.
Usually 3 treatments over
the course of 6 mo are
required.12
Injectable containing
microparticles of PLLA,
carboxymethylcellulose
nonpyrogenic mannito
and sterile water for
injection.*
Sculptra (formerly New-Fill)
(Galderma, Fort Worth,
TX), 2 3 150-mg vials
$482***
CaHA
GOR: C
Six observational studies
with LOE 4.
Acts as a space-filling bulk
for soft tissue augmenta-
tion. Degradation of the
gel carrier then leaves the
CaHA microspheres in the
dermis, which promotes
new skin tissue formation
via fibroblastic growth
and new collagen depo-
sition. Over time the
CaHA microspheres are
metabolized via macro-
phage phagocytosis.12
High viscosity (;350 cPa)
and high elasticity
(;1.5 Pa). CaHA micro-
particles are made of cal-
cium and phosphate ions
identical to bone, which
results in outstanding
biocompatibility with the
human body.12
CaHA microspheres (25-4
m) suspended in a ge
carrier of sodium
carboxymethylcellulose
glycerin, and sterile wa r
for injection.y
Radiesse (formerly Radiance
FN) (Merz Aesthetics,
Franksville, WI),
1 3 1.5-mL syringe
$236***
An implant composed of
spherical CaHA particle
75-125 m in diameter
suspended in an aqueo -
based gel carrier
composed of sodium
carboxymethylcellulose
sterile water for injectio ,
and glycerin.z
Coaptite (Merz Aesthetics,
Franksville, WI)
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HA
GOR: C
Six observational studies
with LOE 4 and 1 case
report with LOE 5.
Acts as a filling substance in
the skin and helps to
retain water. After
treatment, HA chains are
released from the injected
gel carrier and are
biodegraded by natural
mechanisms.47
Highly cohesive gel (;40
gmf) with great density
(G9) (;300 Pa) and
viscoelastic properties.
These properties allow for
high and long-lasting
lifting capacity with small
changes in volume of
implant. HA fillers are
considered nonirritant,
nontoxic, nonsensitizing,
and nonpyrogenic.12,88
A gel of HA isolated from a
Streptococcus species that
is chemically cross-linked
with BDDE, stabilized, and
suspended in phosphate
buffered saline at pH 7
and a concentration of
20 mg/mL.x
Restylane (Galderma, Fort
Worth, TX), 1 3 1-mL
syringe
$160***
Restylane SubQ has fewer
gel particles and larger
droplets than other
Restylane products. It is
more viscous and is
suitable for larger
injection volumes at a
deeper skin layer.47
Restylane SubQ (Galderma,
Fort Worth, TX)
Varies
Restylane-L has the same
formulation as Restylane
with 0.3% lidocaine.//
Restylane-L (Galderma,
Fort Worth, TX)
Varies
A gel of HA generated by
Streptococcus species of
bacteria that is chemically
cross-linked with BDDE,
stabilized, and suspended
in phosphate-buffered
saline at pH 7 and
concentration of 20 mg/
mL.{
Perlane (Galderma, Fort
Worth, TX), 1 3 1-mL
syringe
$186***
A gel composed of cross-
linked molecules of HA
and divinyl sulfone as the
cross-linking agent.#
Hylaform (Genzyme
Corporation, Cambridge,
MA), withdrawn from the
US market
$240yyy
Same formula as Hylaform
with a new source of HA
from bacteria
fermentation.**
Captique (Inamed
Corporation and
Genzyme Corporation,
Santa Barbara, CA),
withdrawn from the
US market
Varies
Continued
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Table II. Cont’d
Filler Mechanism of action Biophysical properties Formulation Trade names
Product
cost, US$##
Same product as Hylaform
with 0.3% lidocaine.yy
Prevelle SILK (Johnson &
Johnson, Skillman, NJ)
Varies
An injectable gel that
consists of cross-linked
HA formulated to a
concentration of 22 mg
mL suspended in a
physiological buffer.zz
Juvederm Ultra/Ultra Plus/
30 (Allergan
Pharmaceutical, Irvine,
CA), 2 3 1-mL syringe
$328***
A gel of cross-linked HA
produced by
Streptococcus equi
bacteria, formulated to
concentration of 20 mg
mL and 0.3% with
lidocaine in a physiolog
buffer.xx
Juvederm Voluma XC (VYC-
20 L) (Allergan
Pharmaceutical, Irvine,
CA), 2 3 1-mL syringe
$367***
High density (26 mg/mL)
nonanimal HA.52
STYLAGE XL (Laboratoires
VIVACY, Paris, France),
2 3 1-mL syringe
$427zzz
HA manufactured from
streptococcal culture
cross-linked with a
binding agent (BDDE) a
reconstituted in a
physiologic buffer at pH
and concentration of
22.5 mg/mL.////
Belotero Balance (Belotero
Basic outside of the US)
and Belotero Intense
(Merz Aesthetics,
Franksville, WI), 5 3 1-mL
syringe
$209xxx
PAAG
GOR: C
One RCT with LOE 2b and
8 observational studies
with LOE 4.
Acts as a nonresorbable soft
tissue filler with a moder-
ate foreign-body
response, but little to no
resultant fibrosis around
the implant.54
Plasticity of PAAG is similar
to that of silicone, and
PAAG is hydrophilic, al-
lowing for high capacity
water exchange with sur-
rounding tissue.54
A gel that contains 2.5%
PAAG and 97.5% water
Aquamid (CONTURA
INTERNATIONAL A/S,
Soeborg, Denmark),
1 3 1-mL syringe
$611//////
2.5% Cross-linked
polyacrylamide and
nonpyrogenic water.
Eutrophill (Trillium Meditec
Inc, Ontario, Canada)
Varies
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PAIG
GOR: D
One RCT (with 2 follow-
up studies) with LOE 2b
and 8 observational
studies with LOE 4.
Induces host tissue to form
a fibrous capsule around
the deposit.61
A nonresorbable,
biocompatible compound
that has a reticulated
structure resembling that
of an adipose tissue. It has
a pH of 7 and an oxidative
value of approximately
0.69
A polymer gel composed of
96% apyrogenic water
and 4% polyalkylimide.62
Bio-Alcamid (Polymekon,
Brindisi, Italy)
Varies
PMMA
GOR: C
Six observational studies
with LOE 4.
Over 1-3 mo after injection
the nonbiodegradable
PMMA microspheres act
as a frame to support the
deposit of conjunctive
tissue and are encapsu-
lated by fibroblasts and
collagen.71
Resembles that of bone
cement and has been
used as a bio-expander
in knee and intraocular
implants.74
An implant composed of
PMMA particles, 30-50 m
in diameter, mixed with
magnesium-carboxy-
gluconate-hydrolactic gel
(ratio microspheres to gel
is 3:10).72
Metacrill (Nutricel
Laboratorios, Rio de
Janeiro, Brazil)
Varies
An implant composed of
nonresorbable PMMA, 30-
50 m in diameter, that is
suspended in a water-
based carrier gel
composed of 3.5% bovine
collagen, 92.6% buffered,
isotonic water for
injection, 0.3% lidocaine
hydrochloride, 2.7%
phosphate buffer, and
0.9% sodium chloride.{{
Artefill/Artecoll (Artes
Medical Inc, San Diego,
CA), 1 3 0.5-mL syringe
$595//////
Silicone oil
GOR: C
Two observational studies
with LOE 4.
Remains permanently in the
skin without undergoing
significant loss; the for-
mation of a collagen
capsule around the mi-
crodroplets may maintain
the position of the
droplets.71
Requires small injection
(microdroplet serial punc-
ture technique) to sub-
dermal plane to avoid
papule formation and
granulomatous reactions.
Medical-grade highly puri-
fied silicone oil (viscosity
1000 centistokes).79
Silikon 1000 (Alcon
Laboratories, Fort Worth,
TX)
Varies
VitreSil 1000 (Richard James
Inc, Peabody, MA)
Varies
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Table II. Cont’d
Filler Mechanism of action Biophysical properties Formulation Trade names
Product
cost, US$##
Autologous fat transfer
GOR: C
Six observational studies
with LOE 4.
Fat transfer Derived from subject’s own
body, fat transfer has the
same biophysical
properties as that of
subject’s own adipose
tissue.
Not applicable Various techniques Varies
BDDE, 1,4-Butanediol diglycidyl ether; CaHA, calcium hydroxylapatite; GOR, grades of recommendation; HA, hyaluronic acid; LOE, levels of evidence; PAAG, polyacrylamide gel; PAIG, polyalkylimide
gel; PLLA, poly-L-lactic acid; PMMA, polymethylmethacrylate; RCT, randomized controlled trial.
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Table III. Expert opinion and recommendation of filler agents for aesthetic treatment of HIV facial lipoatrophy
Filler agents
Expert opinion and recommendation based upon
published studies and clinical experience
PLLA
(FDA approved in 2004, GOR: B)
PLLA is an effective option for treatment of HIV FLA. PLLA may be best for
patients who require treatment over temples and cheeks, as PLLA
provides a gradual and softer fill. PLLA may be considered for global fill of
large areas, as PLLA is easy to massage into adjacent tissues and able to
achieve large spread effect. However, methods for prevention and
management of subcutaneous nodules require further investigation. We
have found in clinical practice that PLLA is relatively easy to use to treat
HIV FLA. However, because of the need for several treatments to achieve
sustained results, best outcomes are often achieved by combining
additional filler agents. GOR: B for PLLA treatment of HIV FLA based on 3
RCTs (with 2 follow-up studies) with LOE 2b, 20 observational studies with
LOE 4, and 4 case reports with LOE 5.
CaHA
(FDA approved in 2006, GOR: C)
CaHA is an effective and safe option for treatment of HIV FLA. The FDA
indication for CaHA is subdermal implantation, and we believe that CaHA,
which is essentially liquid bone, may be best used deeply over bone for
focal enhancement as it provides a firmer fill and does not easily spread to
adjacent tissues. Because of the firm consistency of CaHA, injecting larger
volumes may result in an ‘‘overfilled’’ appearance. GOR: C for CaHA
treatment of HIV FLA based on 6 observational studies with LOE 4.
HA
(Off-label, GOR: C)
HA dermal filler is an effective and safe treatment for HIV FLA. HA dermal
filler has the advantages of achieving immediate results with 1 treatment
and reversibility with hyaluronidase injectables for overcorrection or
adverse events. We envision future research with HA dermal fillers for
treatment of HIV FLA will be important to establish HA’s long-term
efficacy and safety. GOR: C for HA treatment of HIV FLA based on 6
observational studies with LOE 4 and 1 case report with LOE 5.
PAAG
(Off-label, GOR: C)
PAAG is an effective treatment for HIV FLA. However, studies reported small
papules and nodule formation, which may affect patient safety and QoL.
Additional studies are needed to determine long-term safety. GOR: C for
PAAG treatment of HIV FLA based on 1 RCT with LOE 2b and 8
observational studies with LOE 4.
PAIG
(Off-label, GOR: D)
PAIG is an effective treatment for HIV FLA. However, some studies
demonstrated granulomas or infectious complications that required
antibiotics or incision and drainage, which is a significant patient safety
concern. Additional studies are needed to determine long-term safety.
GOR: D for PAIG treatment of HIV FLA safety concerns despite 1 RCT (with
2 follow-up studies) with LOE 2b and 8 observational studies LOE 4.
PMMA
(Off-label, GOR: C)
PMMA is an effective treatment for HIV FLA. Because of PMMA’s mechanism
of action of inducing a foreign-body reaction, additional studies are
needed to determine long-term safety. GOR: C for PMMA treatment of HIV
FLA based on 6 observational studies with LOE 4.
Silicone oil, microdroplet technique
(Off-label, GOR: C)
Silicone oil is an effective treatment for HIV FLA. The microdroplet technique
for silicone oil injection requires expert training and a skilled physician to
minimize risks of microgranuloma formation. Additional studies are
needed to determine long-term safety. GOR: C for silicone oil for
treatment of HIV FLA based on 2 observational studies with LOE 4.
AFT
(Off-label, GOR: C)
AFT is an effective treatment for HIV FLA. However, patients with HIV FLA
likely have generalized HIV lipoatrophy, and AFT may not be optimal
despite proven safety. GOR: C for AFT treatment of HIV FLA based on 6
observational studies with LOE 4.
AFT, Autologous fat transfer; CaHA, calcium hydroxylapatite; FDA, Food and Drug Administration; FLA, facial lipoatrophy; GOR, grades of
recommendation; HA, hyaluronic acid; LOE, levels of evidence; PAAG, polyacrylamide gel; PAIG, polyalkylimide gel; PLLA, poly-L-lactic acid;
PMMA, polymethylmethacrylate; QoL, quality of life; RCT, randomized controlled trial.
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time of 2.8 years and 8 cases of ongoing nodule
formation.
Eight different observational studies63,66-72 (LOE
4) evaluated the safety and efficacy of PAIG for
treatment of HIV FLA. Two different studies revealed
long-term adverse effects of infectious complications
with 19%63 and 3.3%70 of patients.
Grade of recommendation: D for PAIG treatment
of HIV FLA safety concerns despite 1 RCT (with 2
follow-up studies) with LOE 2b and 8 observational
studies LOE 4.
Polymethylmethacrylate
PMMA is a synthetic nonreabsorbable polymer.
PMMAmicrospheres induce a foreign-body reaction,
become encapsulated in fibrous connective tissue,
and result in long-lasting facial augmentation.73
Six observational studies evaluated the efficacy
and safety of PMMA for treatment of HIV FLA74-79
(LOE 4). One study revealed significant improve-
ment in patient QoL and median visual analog scale
score at 2 years.79 A different study demonstrated
85.7% of patients were satisfied at 12 months75 and
90% of patients were satisfied at 5 years in another
study.74
Grade of recommendation: C for PMMA treatment
of HIV FLA based on 6 observational studies with
LOE 4.
Silicone oil
Silicone oil is nonreabsorbable and stimulates a
foreign-body fibrotic reaction around the silicone
deposit.73 For silicone oil, we found 2 observational
studies that used the microdroplet serial puncture
techniquewith injection volumeof 0.01mLperdepot.
One observational study demonstrated that FLA
severity of 1, 2, and 3 as measured by FLA Severity
Scale requires at least 3, 5, and 8 treatments,
respectively80 (LOE 4). A different observational
study showed that 75% of patients had significant
correction of FLA severity as measured by FLA
Severity Scale after median of 6 treatments81 (LOE
4). No severe adverse effects were reported.
Grade of recommendation: C for silicone oil for
treatment of HIV FLA based on 2 observational
studies with LOE 4.
Autologous fat transfer
AFT using Coleman82 lipostructure technique was
first described in 1997 for improving facial contours
and volume.
Four observational studies evaluated the efficacy
and safety of AFT for treatment of HIV FLA83-86 (LOE
4). Improvement of FLA severity was sustained forat least 1 year in 2 studies83,84 and up to 4 years in
1 study.86 Two observational studies evaluated the
use of either AFT or PAAG for treatment of HIV
FLA87,88 (LOE 4). Results from 1 study at 1 year
demonstrated significant improvement in Global
Aesthetic Improvement Scale score in 78.3% of
patients who received AFT treatment compared
with 4.3% who received PAAG treatment.87
Grade of recommendation: C for AFT treatment of
HIV FLA based on 6 observational studies with LOE 4.
Expert recommendation
PLLA (Sculptra) and CaHA (Radiesse) are FDA
approved for treatment of HIV FLA. Comparing PLLA
and CaHA, CaHA provides immediate and lasting
filling properties, whereas PLLA results in an
immediate fill based on sterile water volume that is
temporary and gets absorbed within 1 week. In
addition, PLLA requires 3 treatments in 6 months
before durable aesthetic benefit. PLLA provides a
‘‘softer’’ and more gradual volumizing effect
compared with CaHA because of the mechanism of
action. CaHA provides immediate volumizing fill and
may be thought of as ‘‘liquid bone,’’ whereas PLLA
works as a scaffold stimulating fibroblast migration,
proliferation, and collagen production. Although not
FDA approved for treating HIV FLA, 20 mg/mL of HA
(Voluma) is FDA approved to increase the volume
for mid-facial atrophy. Some benefits include:
immediate corrective effect without the need to
retreat within a 6-month period (as with PLLA), no
need to reconstitute (as with PLLA), and reversible
with hyaluronidase (compared with PLLA and
CaHA). Detailed recommendations of reviewed filler
agents can be found in Table III.
PLLA may be best for patients who require
treatment over temples and cheeks, as PLLA provides
a gradual and softer fill, but at a higher cost because
of multiple treatments and in-office visits, along with
delayed durable visible improvement. PLLA may be
considered for large areas, as PLLA is easy tomassage
into adjacent tissues and able to achieve large spread
effect. The FDA indication for CaHA is subdermal
implantation, and we believe that CaHA may be best
used deeply over bone for focal enhancement as it
provides a firmer fill and does not easily spread. HA,
as a natural component of the skin, has intermediate
elasticity and viscosity, and is able to provide
high volumization properties with minimal gel
migration.89 Both CaHA and HA only require 1
treatment and provide immediate visible improve-
ment, which helps minimize health care and patient
cost. HA is not FDA approved for treatment of HIV
FLA, and our research group (principal investigator
Dr Jagdeo, ClinicalTrials.gov NCT02342223) is
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HA for treatment of HIV FLA. We envision future
head-to-head clinical trials with PLLA, CaHA, and HA
will be of significant importance to compare and
contrast these agents for treatment of HIV FLA.
DISCUSSION
Although clinical studies differed with respect to
filler injection volumes and follow-up periods, all
filler agents discussed in our review showed
improvement in HIV FLA severity by 12 weeks.
Studies demonstrated sustained improvement in
HIV FLA severity for at least 12 months with PLLA,
CaHA, HA, and silicone oil injections, and up to 4 to
5 years with AFT, PAAG, PAIG, and PMMA injections.
The degree and duration of improvement for each
treatment option is closely related to initial HIV FLA
severity and the biophysical and longevity profile
distinct to each filler agent.
Filler agents for treatment of HIV FLAwere shown
to be safe and well tolerated by most patients.
Common transient adverse effects because of the
nature of filler injections include pain and
discomfort, ecchymosis, edema, and erythema that
usually resolve by 1 month. Treatment with PLLA
was associated with occasional subcutaneous
nodules. Immunosuppression may be beneficial in
reducing the incidence of immunologically related
filler agent reactions such as granulomas, although
HIV immunosuppression may increase infections
associated with filler agent procedures. Based on
long-term patient follow-up, silicone oil using the
microdroplet technique does not induce palpable
nodules in patients with HIV, and it is possible that
their HIV disease is beneficial toward this outcome.81
Future research studies should incorporate larger
sample sizes to adequately power for statistical
significance, along with RCTs and longer follow-up
periods to evaluate the long-term efficacy and
safety for each filler agent for aesthetic treatment of
HIV FLA.
Limitations
PLLAwas the only filler agent to receive a GOR: B
based on several RCTs. We found limited RCTs that
evaluated the use of other filler agents for aesthetic
treatment of HIV FLA. As a result, CaHA, HA, PAAG,
PAIG, PMMA, silicone oil, and AFT for treatment of
HIV FLA received a GOR: C or D.
Other limitations with many published studies
include follow-up periods of 12 or 18 months, which
may be insufficient to demonstrate the long-term
efficacy and safety as filler agents may last 12 months
or longer. Duration on HAART and patients’ ages
were not clearly stated, which may introduce bias asHIV FLA tends to be more severe with prior
generations of HAART and normal aging may also
result in significant facial volume loss, respectively.
Washout periods were inconsistent or not stated
across all studies, which could affect filler efficacy
and longevity. Interstudy comparison among
studies was difficult as different objective and
subjective grading scales were used. Future
researchers may consider objective grading scales
such as skin thickness or volume measurement by
ultrasound or 3-dimensional imaging, or standard-
ized subjective grading scales such as Global
Aesthetic Improvement Scale or FACE-Q. In
addition, not all researchers have adopted the
Carruthers Lipoatrophy Severity Scale to grade HIV
FLA. This leads to inconsistency among studies for
determining baseline severity and improvement
post-HIV FLA treatment. As a result of these factors,
independent objective improvement from various
types of fillers treated for patients with different HIV
FLA severity could not be determined. Furthermore,
the reviewed clinical trials evaluated different classes
and brand-specific formulations of fillers, and some
fillers may not be currently available on themarket or
may be limited to specific countries. In addition,
treatment for HIV FLA may be an out-of-pocket
patient expense not covered by insurance, and
researchers may consider incorporating cost-
effectiveness analysis in future clinical trials to better
comprehend improvement as related to price.
Conclusion
The current literature suggests that filler agents for
treatment of HIV FLA are an effective and generally
safe option for aesthetic improvement and help
improve patient QoL. Treatment of HIV FLA is
important because it affects patients’ psychological
health, QoL, and adherence to HIV treatment
regimen. Many filler agents exist, and when the
clinician and patient decide on a treatment regimen
for HIV FLA, factors such as cost, FDA approval,
frequency of treatment sessions, time required until
improvement, and filler longevity are important for
consideration. There is currently a lack of clinical
evidence on the treatment of HIV FLA that would
suggest a specific filler over others as filler agents
each have unique biophysical properties. Based on
published studies, PLLA is the only filler agent with
GOR: B. Other reviewed filler agents received GOR:
C or D. We hope future researchers will implement
more RCTs with direct head-to-head comparisons to
evaluate the efficacy and safety of different fillers, in
conjunction with cost-effectiveness analysis, for
treatment of HIV FLA. In the future, we envision
there will be an objective method for selecting a filler
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cost, and filler longevity accompanied by the
development of longer-lasting, semipermanent,
reversible filler agents for treatment of HIV FLA.
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Supplemental Table I. Clinical studies on treatment of HIV facial lipoatrophy using filler agents
No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
PLLA (grade of recommendation: B)
1 Moyle et al,13 2004 2b Randomized, open-label; facial
ultrasound, VAS, HADS
30 Subjects
Inclusion:
- Moderate to severe nasolabial
fat pad loss
- NopreviousHIV FLA treatment
Significant improvement in
dermal thickness, VAS, and
HADS scores was observed at
wk 12 in the immediate
group, and in both
immediate and delayed
groups at wk 24
2 Adverse events: bruising
(n = 1) and limited superficial
local cellulitis not requiring
antibiotic therapy (n = 1)
2 Moyle et al,14 2006 2b Follow-up; VAS, HADS 27 Subjects
Inclusion:
- Moderate to severe nasolabial
fat pad loss
- No previous HIV FLA treatment
Improvements in all scores
persisted to the recall visit;
improvements in depression
only reached statistical
significance in the delayed
group
1 Case of injection-site
induration and 9 cases of
injection-site nodules were
noted at the recall visit (not
described as serious or
severe)
3 Carey et al,15 2007 2b Randomized, open-label,
multicenter; change in
FSTV by CT imaging,
SF-36, MBSRQ-AS
100 Subjects
Inclusion:
- Moderate to severe HIV FLA
with lipodystrophy at $1
sites
At wk 24, FLA severity and
some QoL domains were
improved; tissue thickness in
injection planes increased,
but PLLA injection did not
increase FSTV
6 Subjects had nodule/papule
formation at wk 24
4 Carey et al,16 2009 2b Follow-up; change in FSTV by
CT imaging, SF-36, MBSRQ-
AS
100 Subjects
Inclusion:
- Moderate to severe HIV FLA
with lipodystrophy at $1
sites
At wk 48, the mean change in
FSTV was 14 mL in the
immediate group and 18 mL
in the deferred group
10 Subjects had sustained
nodule/papule formation at
wk 48
5 Narciso et al,17 2009 2b Randomized, controlled, open-
label, single center; FLA
Severity Scale from grade
1-5, EQ-5D, ISSQoL Core
Evaluation Form
134 Subjects
Inclusion:
- Severe HIV FLA
- CD4 count[100
Exclusion:
- Previous filling surgery
Immediate treatment group
had significantly lower FLA
severity scores compared
with delayed treatment
group; similar efficacy was
demonstrated with PLLA and
PAIG
Mild and transient
6 Valantin et al,18 2003 4 Case series; facial ultrasound,
VAS
50 Subjects
Inclusion:
- HAART for $3 y
- HIV1 RNA level\5000
copies/mL
Exclusion:
- Facial implant in last 6 mo
Median TCT increased
significantly from baseline
and persisted to wk 96 (43%
with TCT[10 mm)
Nonvisible subcutaneous
papules (44%) with
spontaneous resolution in 6
subjects at wk 96
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Fin ngs Adverse events
7 Borelli et al,19 2005 4 Case series; facial ultrasound 14 Subjects
Inclusion:
- Age[18 y on HAART
Skin thickness creased in all
subjects at 6 o follow-up
No serious side effects reported
during treatment or follow-
up
8 Burgess and Quiroga,20 2005 4 Case series; treatment
evaluation scale grade 1-4,
subjective evaluation by
subject, treating physician,
and a nontreating physician
61 Subjects
Inclusion:
- On HAART for at least 1 y
All subjects ha positive
improvemen at 6-mo
follow-up; s ificant
improvemen was sustained
for 6 mo in subjects, for
1 y in 10 su ects, for 18 mo
in 9 subjects nd for $2 y in
5 subjects
2 Subjects developed
persistent, asymptomatic,
palpable papules
9 Guaraldi et al,21 2005 4 Case series; facial ultrasound,
ABCD questionnaire, VAS,
pretreatment and
posttreatment photograph
assessment by independent
reviewers
59 Subjects
Inclusion:
- On HAART for at least 6 mo
Exclusion:
- CD4 count\100
All corrective o tions (AFT and
PLLA) appea d highly
effective in rrecting fat
wasting; me subcutaneous
thickness in ased by
3.5 mm afte 4 wk and was
equivalent f each
intervention esthetic
satisfaction s significantly
improved; th AFT group
was less sat ied with body
image at th nd of
treatment
AFT (n = 4 with disfiguring fat
graft hypertrophy of the
face)
PLLA (n = 8 developed
nonvisible palpable papules)
10 Lafaurie et al,22 2005 4 Case series; VAS, photographs,
3D photographs, MOS SF-36
94 Subjects
Inclusion:
- CD4 count[200
- Stable HAART for at least
3 mo
Exclusion:
- History of surgical or cosmetic
intervention for HIV FLA
Median VAS in eased
significantly d was
sustained at compared
with 3.4 at b seline; median
dermal thick ess increased
2.3 mm
Palpable nodules (13%)
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
11 Cattelan et al,8 2006 4 Case series; facial ultrasound,
MOS-HIV
50 Subjects
Inclusion:
- Moderate or severe HIV FLA
- HIV RNA level\1000 copies/
mL
- CD4 count[100
Exclusion:
- Prior facial implants
Mean TCT increased
significantly to 4.3 mm and
4.4 mm on the right and left
cheeks, respectively; at
12-mo, improvements
maintained at 3.4 mm and
3.3 mm
Transient and mild
12 Mest and Humble,23 2006 4 Case series; caliper skin
thickness, study
questionnaire
97 Subjects
Inclusion:
- $18 y with clinically signifi-
cant HIV FLA
Exclusion:
- Facial injection within past
3 mo
75 Subjects achieved
statistically significant mean
increase in dermal thickness
of 4.2 mm at 12 mo; subject
satisfaction was very high
throughout
Bruising (30.3%) and papules
(13.1%)
13 Negredo et al,24 2006 4 Case series; photograph
assessment by 2
independent observers,
DEXA scan, MOS-HIV
138 Subjects
Inclusion:
- On HAART for $6 mo
- CD4 count[100
Exclusion:
- Previous cosmetic facial inter-
vention
All treatments (AFT, PLLA, and
PAIG) demonstrated
significant immediate
improvement in FLA and
results regressed at wk 48 in
all groups; PAIG had the best
and AFT had the worst long-
term result at wk 48
No adverse events reported
14 Hanke and Redbord,25 2007 4 Case series; subjective
assessment via HIV FLA
grade 1-5, subject
satisfaction scale grade 1-5
65 Subjects
Inclusion:
- Subjects with HIV FLA
HIV FLA score decreased a
mean of 2.34 after treatment;
age-related FLA score
decreased a mean of 1.2 after
treatment
Transient subcutaneous
papules (n = 2)
15 Ong et al,26 2007 4 Case series; 3D laser scans,
subjective assessment from
0-3 to a casual observer,
HADS, RSE
51 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- History of facial implants
Significant immediate
improvement of clinical and
subjective scores at 6 mo,
followed by a pattern of
gradual deterioration in
clinical grading scores and
measures of psychological
well-being at 24 mo
Not available
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
16 Orlando et al,27 2007 4 Case series; facial ultrasound,
VAS, ABCD questionnaire,
BDI
299 Subjects
Inclusion:
- On HAART for at least 6 mo
Exclusion:
- Previous HIV FLA treatment
All subjects (AFT- and PLLA-
treated) showed significant
improvement of aesthetic
satisfaction for the face and
had significant augmentation
of both cheeks’ thickness
(right cheek, 4.3-9.5 mm; left
cheek, 4.4-9.6 mm)
Nonvisible, subcutaneous
micronodules (45% PLLA-
treated subjects)
17 Kavouni et al,28 2008 4 Case series; subjective
measurement by PI, HADS,
Appearance Satisfaction
Questionnaire
411 Subjects
Inclusion:
- $18 y with stable CD4 count
- Presence of HIV FLA
measured by Chelsea and
Westminster scale
Subject anxiety, depression,
and appearance satisfaction
scores significantly improved
posttreatment
Nodule formation (2.9%)
18 Levy et al,29 2008 4 Case series; subjective
photograph review by
blinded physicians and
graded on scale of 1-5
65 Subjects
Inclusion:
- Subjects with HIV FLA
At 3 y, statistically significant
improvement in FLA scores
Subcutaneous papules (11%) at
3 y
19 Nelson and Stewart,30 2008 4 Case series; 3D facial imaging,
VAS
46 Subjects
Inclusion:
- Subjects with HIV FLA
Aesthetic improvement was
‘‘moderate’’ and required 7
treatment sessions
Transient and mild
20 Mest and Humble,31 2009 4 Case series; caliper skin
thickness, subjective
photograph review by
physicians
65 Subjects
Inclusion:
- Clinically significant HIV FLA
after previous treatment with
PLLA in the Blue Pacific study
Approximately 10% of subjects
had persistent correction at
36 mo
Small, nonvisible papules
(7.7%)
21 Ong et al,32 2009 4 Case series; 3D laser surface
scanning, HADS, RSE, DAS59
100 Subjects
Inclusion:
- $18 y with HIV FLA
confirmed by 2 physicians
Exclusion:
- History of facial implant
Clinical scores improved from a
‘‘moderate-severe’’ grade to
‘‘non-mild’’ grade
posttreatment, and
significant improvements in
all psychological outcomes;
3D laser surface scans
showed a volume increase of
2.81 mL
Bruising (7.5%) and
subcutaneous lumps (3.3%)
resolved at 1-y follow-up
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
22 Bassichis et al,33 2012 4 Case series; MOS-HIV, Facial
Appearance Questionnaire,
subject and physician
satisfaction assessment by
5-point Likert scale
290 Subjects;
Inclusion:
- $18 y and HIV positive
Exclusion:
- Previous treatment with
injectable PLLA or other
product for HIV FLA
Mean significant improvement
in FLA score was 1.4; 89.4%
of subjects and 95.5% of
physicians rated treatment
satisfaction as ‘‘very good’’ or
‘‘excellent’’
At 2 y, injection-site nodules
(8.3%) and papules (8.6%)
23 Lafaurie et al,34 2013 4 Case series; VAS, 3D
photographs, MOS SF-36
148 Subjects
Inclusion:
- CD4 count[200
- Stable HAART for at least
3 mo
Exclusion:
- History of surgical or
cosmetic intervention for HIV
FLA
At wk 48, mean VAS increased
from baseline of 2.8 to 7.1
and 7.5 in PLLA and PAAG
groups, respectively; at wk
96, VAS maintained at 6.7
and 7.9, respectively
Subcutaneous nodules (41% in
PLLA-treated subjects and
37% in PAAG-treated
subjects); 4 PAAG-treated
subjects developed severe
inflammatory nodules
24 van Rozelaar et al,35 2014 4 Case series; regional total
subcutaneous thickness by
MRI, SF-36, MOS-HIV
82 Subjects
Inclusion:
- $18 y with CLSS grade 2-4
Exclusion:
- Earlier use of facial fillers
Significant increase in total
subcutaneous thickness in
nearly all subjects 1-y
posttreatment; subjects
reported improved QoL with
increased score in mental
health, social, and role
functioning, and decreased
depressive symptoms
Hematomas (n = 5) that
spontaneous resolved;
nodule formation (n = 6);
inflammation (n = 3)
25 Wang et al,36 2014 4 Case series; subjective clinical
assessment by physician
3 Subjects
Inclusion:
- Subjects with HIV FLA
All 3 subjects benefited from
visible augmentation of
cheek contours; this filling
technique accentuated
dynamic cheek fullness and
movement associated with
smiling
No adverse events reported
26 Vleggaar and Bauer,37 2004 5 Case report; subjective clinical
assessment by physician
2 Subjects
Inclusion:
- Subjects with HIV FLA
Aesthetic effect was visible at
12 mo and maintained at
24 mo
Not reported
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
27 Wildemore and Jones,38 2006 5 Case report; subjective clinical
assessment by physician
1 subject;
Inclusion:
- Subject with HIV FLA
3 y Posttreatment, skin biopsy
specimen of persistent red
bumps revealed marked
foreign-body giant-cell
reaction with numerous
fragments of polarizable
foreign material and
surrounding dermal fibrosis
Persistent red bumps
28 Kates and Fitzgerald,39 2008 5 Case report; subjective clinical
assessment by physician
2 Subjects
Inclusion:
- Subjects with HIV FLA
At 12 mo, there was no papule
formation
Mild and transient
29 Mest and Humble,40 2009 5 Case report; subjective clinical
assessment by physician
1 Subject
Inclusion:
- Subject with HIV FLA
FLA correction maintained at
2 y and 7 mo posttreatment
No adverse events reported
CaHA (grade of recommendation: C)
1 Comite et al,41 2004 4 Case series; subjective clinical
assessment by physician
3 Subjects
Inclusion:
- Subjects with HIV FLA
Significant improvement after
initial treatment (75%-90%)
with some loss of
improvement at 9 mo
(55%-90%)
None reported
2 Silvers et al,42 2006 4 Case series; GAIS 100 Subjects
Inclusion:
- CD4 count[250
- HIV RNA level\5000 copies/
mL
- On HAART for at least 3 y
100% of subjects who followed
up were ‘‘improved or
better’’ at 12 mo and 91% at
18 mo; improvement in skin
thickness measurements was
sustained at 12 mo
Mild and transient
3 Carruthers et al,43 2008 4 Case series; x-ray, CT scans to
blinded radiologists
58 Subjects
Inclusion:
- Subjects with HIV FLA
CT showed consistent
visualization of CaHA
immediately after treatment
whereas x-ray did not
Not reported
4 Carruthers and Carruthers,44
2008
4 Case series; GAIS by a blinded
observer, change in cheek
thickness
30 Subjects
Inclusion:
- CD4 count[250
- HIV RNA level\5000 copies/
mL
- On HAART for at least 3 y
- CLSS grade 2, 3, or 4
Exclusion:
- Any collagen or silicone in-
jections in the cheek area in
previous 6 mo
Cheek thickness measurements
increased substantially over
baseline; subjects were rated
as ‘‘improved or better’’ on
the GAIS, and subject
satisfaction was ‘‘very high’’
Mild and transient
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
5 Alam et al,45 2011 4 Case series; subjective clinical
assessment by physician
3 Subjects
Inclusion:
- Subjects with HIV FLA
All subjects self-reported 50%
improvement at 15 mo
Mild and transient
6 Rauso et al,46 2013 4 Case series; subjective clinical
assessment by physician
26 Subjects
Inclusion:
- CD4 count[250
- HIV RNA level\5000
copies/mL
Exclusion:
- Previous facial injection of
any other products
High subject satisfaction was
achieved with all subjects
Mild and transient
HA (grade of recommendation: C)
1 Ritt et al,48 2001 4 Case series; subjective clinical
assessment by physician
7 Subjects
Inclusion:
- Subjects with HIV FLA
Subjects had positive reactions
from their social
environment and were
satisfied with their treatment;
authors recommended
injections should be
subcutaneous rather than
intradermal for better
treatment outcome
Mild and transient
2 Gooderham and Solish,49 2005 4 Case series; subjective clinical
assessment by physician
5 Subjects
Inclusion:
- Subjects with HIV FLA CLSS
grade 2 or 3
‘‘Good’’ cosmetic result and
improvement was
maintained at 6 mo
Mild and transient
3 Denton and Tsaparas,50 2007 4 Case series; facial assessment
using a 7-point Likert scale
18 Subjects
Inclusion:
- Clinically evident HIV FLA
- On HAART for at least 3 mo
Exclusion:
- Previous malar augmentation
in previous 2 y
Significant early improvement
that maintained at 12 mo
with high subject satisfaction
1 Subject who previously
underwent external beam
radiation for Kaposi sarcoma
had prolonged palpability,
erythema, and telangiectasia
up to 4 mo
4 Bechara et al,51 2008 4 Case series; GAIS, DLQI 21 Subjects
Inclusion:
- CD4 count[250
At 3 mo, 19 subjects were
‘‘much improved’’ and 2
subjects were ‘‘improved’’
and received a touch-up; at
12 mo, 16 subjects were
‘‘much improved’’ and 4
‘‘improved’’; subject
satisfaction was high and
subject QoL improved
Mild and transient
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
5 Skeie et al,47 2010 4 Case series; facial ultrasound,
GAIS, VAS
17 Subjects
Inclusion:
- Severe nasogenian atrophy
that is noticeable to a casual
observer
Exclusion:
- Previous HIV FLA treatment
with injectable fillers
Mean TCT increased from 6 mm
at baseline to 12 mm at
36 mo with response rate
(TCT[10 mm) of 70%;
subject report of facial
appearance, VAS, and self-
esteem scores were
increased
Local swelling and tenderness
were common
posttreatment; persistent
papules in several subjects
were removed effectively
with hyaluronidase injections
6 Pignatti et al,52 2012 4 Case series; facial ultrasound,
GAIS, VAS
54 Subjects
Inclusion:
- HIV FLA ‘‘moderate to severe’’
- On HAART for at least 6 mo
Exclusion:
- Previous injectable fillers
within previous 6 mo
Mean soft tissue thickness of
the cheek increased
significantly from 9.45-
13.12 mm; subject
satisfaction was ‘‘very high’’
Mild and transient
7 Pavicic et al,53 2010 5 Case report; subjective clinical
assessment by physician
2 Subjects
Inclusion:
- Subjects with HIV FLA
Both subjects had FLA score of
0 at 6- and 12-mo follow-up
Mild and transient
PAAG (grade of recommendation: C)
1 Rauso et al,55 2012 2b Randomized, single center;
facial ultrasound
31 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous facial injection
At 12 mo, subjects who
received 8 mL of PAAG in 1
treatment noted faster
improvements than subjects
who received several 2-mL
PAAG treatments; ultrasound
demonstrated no difference
in terms of tissue response in
both groups
Small, nonvisible papules
(n = 6)
2 de Santis et al,54 2008 4 Case series; facial ultrasound,
VAS, ABCD, BDI
50 Subjects
Inclusion:
- On HAART for at least 6 mo
- CD4 count[100
Exclusion:
- Previous permanent filler or
resorbable filler within previ-
ous 6 mo
Mean cheek thickness
improved from mean of 4.5
6 2.5 mm pretreatment to
mean of 8.4 6 2.7 mm at 6-
mo follow-up
Mild and transient
3 Negredo et al,56 2009 4 Case series; subjective clinical
assessment by physician
145 Subjects
Inclusion:
- Subjects with HIV FLA
88.9% of Subjects were
‘‘satisfied’’ or ‘‘very satisfied’’
at 4 y
Small, nonvisible, palpable
nodules (19.3%) and
indurations (6.2%)
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
4 Mansor et al,57 2011 4 Case series; subjective clinical
assessment by blinded
physician, subject
satisfaction on a 4-point
Likert scale, QoL rate on a 5-
point scale
42 Subjects
Inclusion:
- CD4 count[100
- On HAART for at least 1 y
Improvement of FLA score was
observed in all cases: 1-grade
reduction in 11 cases, 2-
grade reduction in 20 cases,
and 3-grade reduction in 3
cases with high subject
satisfaction
None reported
5 Rauso et al,58 2011 4 Case series; facial ultrasound,
VAS
32 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous facial injection with
any other products
Subject satisfaction was ‘‘high’’
during follow-up period;
ultrasound revealed a thin
capsule around the product
with no interaction with
surrounding tissues
Small, palpable, nonvisible
nodules (n = 13)
6 Rauso,61 2015 4 Follow-up; facial ultrasound,
VAS
32 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous facial injection with
any other products
At 5-y follow-up, VAS
demonstrated slight decline
from first year (8.3-7.6); no
complications were observed
Small, palpable, nonvisible
nodules (n = 13), which were
present since the 18-mo
follow-up
7 de Santis et al,59 2012 4 Case series; facial ultrasound,
GAIS, VAS, BDI, ABCD
questionnaire
38 Subjects
Inclusion:
- On HAART for at least 6 mo
- HIV FLA ‘‘moderate to severe’’
Exclusion:
- Previous permanent filler or
resorbable filler within previ-
ous 6 mo at the site
Significant improvement of
cheek thickness, aesthetic
result, satisfaction, and
psychological improvement
over 5-y follow-up
Localized permanent
indurations (n = 4)
Caudal migration of injected
PLLA (n = 3)
8 Mole et al,60 2012 4 Case series; facial ultrasound,
Overall Treatment
Satisfaction score, ABCD
questionnaire
111 Subjects
Inclusion:
- On HAART for at least 3 mo
- CD4 count[100
Exclusion:
- Previous treatment with facial
implants
Mean cheek thickness
improved by average of
4.4 mm at 12 mo and
additional 0.87 mm at 24 mo;
subject QoL and treatment
satisfaction improved over
time
Mild and transient
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
9 Negredo et al,62 2015 4 Case series; subjective clinical
grading by physicians,
subject satisfaction score
using Likert scale from 0-10
104 Subjects
Inclusion:
- Subjects with HIV FLA
After PAAG treatment at least
$10 y, moderate, mild, and
no signs of HIV FLA were
reported in 19.2%, 47.7%,
and 31.7%, respectively;
physicians reported 1.9%,
10.6%, and 87.5%,
respectively; subjects were
highly satisfied (74.8%) and
satisfied (23.4%), and
subjects with severe and very
severe HIV FLA were satisfied
(31.4%) and highly satisfied
(65.7%)
Indurations resulted in 6.7% of
subjects, nodule formation in
3.8% of subjects, and local
infection in 4.8% of subjects
PAIG (grade of recommendation: D)
1 Loutfy et al,9 2007 2b Randomized, open-label, single
center; improvement with
CLSS, MOS-HIV, HADS, sDQLS
31 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous HIV FLA treatment
within past 9 mo
Subjects in the immediate
treatment group had
significantly lower physician-
rated FLA scores, improved
QoL and lower anxiety score
at 12 wk; at 48 wk, FLA scores
remained low in both the
immediate and delayed
treatment groups and
differences between the
groups were minimal
Mild and transient
2 Antoniou et al,64 2009 2b Follow-up; improvement with
CLSS, MOS-HIV, HADS, sDQLS
31 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous HIV FLA treatment
No differences between
immediate and delayed
treatment groups at 96 wk
No long-term adverse events
3 Loutfy et al,65 2011 2b Follow-up; improvement with
CLSS, MOS-HIV, HADS, sDQLS
31 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous HIV FLA treatment
within past 9 mo
Physician and subject CLSS
scores changed a median of
2 and 1 from baseline to
year 4, respectively;
improvements with
depression and anxiety
maintained at 4 y
Infection (n = 5), nodules
(n = 8), and bleeding (n = 1)
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4 Treacy and Goldberg,66 2006 4 Case series; subjective clinical
assessment by physician, BDI
11 Subjects
Inclusion:
- ‘‘Severe’’ HIV FLA
Exclusion:
- Previous HIV FLA treatment
Improvement of FLA severity
was maintained at 18 mo;
QoL improved ‘‘dramatically’’
for all subjects at 3 mo
Mild and transient
5 Ramon et al,67 2007 4 Case series; subjective clinical
assessment by physician
13 Subjects
Inclusion:
- Subjects with HIV FLA
Most subjects had ‘‘good or
excellent’’ results as reported
by subjects and physicians
Small hematoma (n = 1)
6 Honig,68 2008 4 Case series; subjective clinical
assessment by physician
9 Subjects
Inclusion:
- Subjects with HIV FLA
Improvement of FLA with 63%
of cases as ‘‘excellent,’’ 32%
of cases as ‘‘good’’;
correction was maintained at
median of 2-y follow-up
Mild and transient
7 Karim et al,69 2008 4 Case series; subjective clinical
assessment by physician, SF-
36, MOS-HIV, CES-D
17 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Grade-1 HIV FLA
Severity of FLA significantly
decreased at 48 wk and
improvements with QoL in
mental health, social
function, and depression
score
Capsule formation or gel
migration (n = 3); injection-
site infection (n = 1)
8 Schelke et al,70 2009 4 Case series; survey, biopsies 3196 Subjects
Inclusion:
- Subjects with HIV FLA
Subject complication rate was
4.8% and treatment
complication rate 3.3%; the
Dutch Society of Cosmetic
Medicine considered this
overall rate and severity of
the complications too high a
risk for a cosmetic treatment,
thus they advise against use
of PAIG
Inflammation, hardening,
migration, and accumulation
of filler
9 Nelson and Stewart,71 2011 4 Case series; subjective clinical
assessment by physician
7 Subjects
Inclusion:
- Subjects with HIV FLA
Complications in 7 subjects
after PAIG injection
treatment from 2 mo to 3 y,
and 6 subjects developed[1
type of complication
Infection (n = 4), inferior
migration of product (n = 3),
excessive capsule formation
(n = 2)
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No. Authors LOE Study type; efficacy measured
Sample size; inclusion and
exclusion criteria Findings Adverse events
10 George et al,72 2012 4 Case series; subjective clinical
assessment by physician,
subject satisfaction survey
69 Subjects
Inclusion:
- Subjects with HIV FLA
Despite relatively high subject
satisfaction, the authors no
longer recommend this
treatment for cosmetic
indications because of
significant long-term
complication rates
Required removal of PAIG from
the cheek more frequently
than the temple because of
infection (n = 1) or superficial
lump (n = 8); 50% of survey
responders identified at least
1 complication
11 Nadarajah et al,63 2012 4 Case series; subjective clinical
assessment by physician
267 Subjects
Inclusion:
- Subjects with HIV FLA
High incidence of infectious
complications (19%); median
time from initial treatment to
infection was 32 mo
Surgical drainage and
antibiotics were required for
the majority of subjects with
infectious complications
PMMA (grade of recommendation: C)
1 Carvalho Costa et al,74 2009 4 Case series; subjective clinical
assessment by physician
266 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- Previous treatment with any
filler agent
Treatment maintained
significant aesthetic
correction at 5 y
posttreatment; 90% of
subjects were ‘‘satisfied’’ with
the results and achieved
‘‘significant’’ improvement in
self-esteem
Mild and transient
2 Orsi et al,75 2011 4 Case series; subjective clinical
assessment by physician
49 Subjects
Inclusion:
- Subjects with HIV FLA
At 12 mo, 85.7% of subjects
reported satisfaction
Nodular lesion (n = 1)
3 Warde et al,76 2011 4 Case series; SF-36, RSE/
UNIFESP-EPM, BSQ, BDI
40 Subjects
Inclusion:
- Subjects with HIV FLA
Statistically significant
improvement observed in
immediate treatment group
for most aspects of SF-36
questionnaire, and no
observed improvement in
delayed treatment group
Not reported
4 Serra et al,77 2013 4 Case series; improvement in
classification of lipoatrophy
according to a 5-point scale
20 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- CD4 count\200
All subjects had either ‘‘good’’
or ‘‘excellent’’ response to
treatment
Mild and transient
5 Soares and Costa,78 2013 4 Case series; plasma viral load
and CD4 count
44 Subjects
Inclusion:
- On HAART for at least 6 mo
Statistically significant increase
in CD4 count posttreatment
with no significant
improvement with viral load
Not reported
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6 Quintas et al,79 2014 4 Case series; SF-36, HAT-QoL,
VAS, BDI
51 Subjects
Inclusion:
- CD4 count[250
- On HAART for at least 3 mo
Exclusion:
- Previous HIV FLA treatment
Significant improvement of
median VAS and subject QoL
Mild and transient
Silicone oil (grade of recommendation: C)
1 Jones et al,80 2004 4 Case series; improvement with
CLSS
77 Subjects
Inclusion:
- Subjects with HIV FLA
Exclusion:
- History of treatment with per-
manent fillers
The volume of silicone, number
of treatments, and time
required to reach a complete
correction were directly
related to the initial FLA
severity; majority of subjects
were ‘‘very satisfied’’ with
their treatment
Mild and transient
2 Chen et al,81 2013 4 Case series; improvement with
CLSS, Functional Assessment
of HIV Infection QoL
measurement scale
20 Subjects
Inclusion:
- HIV FLA CLSS 2 or 3
- Display $1 metabolic fea-
tures since initiation of
HAART
At 18 mo, FLA severity scores
significantly improved (mean
2.625) compared with
baseline (mean 0.225), and
subject QoL improved from
2.15-4.3
Severe postinjection pain
(n = 1), and severe edema
(n = 2)
AFT (grade of recommendation: C)
1 Strauch et al,83 2004 4 Case series; subjective clinical
assessment by physician
5 Subjects
Inclusion:
- Subjects with HIV FLA
Aesthetic results were
‘‘dramatic and stable,’’ and
maintained at 1- to 2-y
follow-up
Not reported
2 Burnouf et al,84 2005 4 Case series; subjective clinical
assessment by 3 blinded
physicians, subject
satisfaction questionnaire
33 Subjects
Inclusion:
- Subjects with HIV FLA
FLA severity improved in 12
subjects by 3 evaluators, 17
subjects by at least 2
evaluators, and in 25 subjects
by at least 1 evaluator;
subject satisfaction rate of
93% at 1 y
Mild and transient
3 Mori et al,85 2006 4 Case series; subjective clinical
assessment by physician
12 Subjects
Inclusion:
- Subjects with HIV FLA
Both techniques (lipofilling
using Coleman technique
and bilateral malar implants)
resulted in ‘‘good’’ to ‘‘very
good’’ long-lasting results
None reported
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4 Dollfus et al,86 2009 4 Case series; subjective clinical
assessment by physician
6 Subjects
Inclusion:
- Subjects with HIV FLA
Sub
‘
c
r
o
5 Rauso et al,87 2011 4 Case series; GAIS 23 Subjects
Inclusion:
- Subjects with HIV FLA
Sub
h
i
P
a
g
6 Rauso et al,88 2012 4 Case series; subjective clinical
assessment by 2 blinded
physicians, VAS
28 Subjects
Inclusion:
- Subjects with HIV FLA
Me
V
P
8
(
p
d
g
r
F
ABCD, Adult AIDS Clinical Trials Group Assessment of Body Change and Distress; AFT, autologous fat transfer; BDI, Beck D
CaHA, calcium hydroxylapatite; CES-D, Center for Epidemiological Studies Depression scale; CLSS, Carruthers Lipoatrophy Sev
Scale; DEXA, Dual-energy X-ray absorptiometry; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQoL 5 domains; FLA, facia
Improvement Scale; HA, hyaluronic acid; HAART, highly active retroviral therapy; HADS, Hospital Anxiety Depression Scale; ISSQ
MBSRQ-AS, Multidimensional Body-Self Relations Questionnaire-Appearance Scales; MOS-HIV, Medical Outcomes Study-HIV qu
health survey; MRI, magnetic resonance imaging; PAAG, polyacrylamide gel; PAIG, polyalkylimide gel; PLLA, poly-L-lactic acid; P
of life; RSE, Rosenberg Self-Esteem Scale; RSE/UNIFESP-EPM, Brazilian version of the Rosenberg Self-Esteem scale; sDQLS, slightly
Health Survey; TCT, total cutaneous thickness; VAS, visual analog scale score; 3D, 3-dimensional.
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4Findinjects were ‘‘satisfied’’ or
‘very satisfied’’ with the
osmetic results and
eported a positive impact
n daily life
None reported
jects who underwent AFT
ad statistically significant
mprovement compared with
AAG-treated subjects
ccording to physician-
raded GAIS
Mild and transient
an satisfaction score with
AS for both AFT-treated and
AAG-treated subjects was
.7 (subjects) and 7.6
blinded evaluators); authors
resent a triangular area of
epression that provided
ood aesthetic outcome to
estore facial wasting for HIV
LA
None reported
epression Inventory questionnaire; BSQ, Body Shape Questionnaire;
erity Scale; CT, computed tomography; DAS59, Derriford Appearance
l lipoatrophy; FSTV, facial soft tissue volume; GAIS, Global Aesthetic
oL, Istituto Superiore di Sanita’ Quality of Life; LOE, levels of evidence;
estionnaire; MOS SF-36, Medical Outcome Study Short Form 36-item
MMA, polymethylmethacrylate; PI, principal investigator; QoL, quality
modified Dermatology Quality of Life Survey; SF-36, Short Form 36v2
J
A
M
A
C
A
D
D
E
R
M
A
T
O
L
D
E
C
E
M
B
E
R
20
15
Ja
gd
eo
et
a
l
